A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)

Key Inclusion Criteria: * Patients with involvement of at least 2 anatomical areas at screening and baseline * Patients need to have an IGA hand and foot score of 3 or 4 (moderate-to-severe disease) at screening and baseline * Patients with documented recent history (within 6 months before the screening visit) of inadequate response of atopic hand and foot dermatitis to topical medication(s) * Patients meet the diagnosis criteria for atopic dermatitis (AD) * Provide informed consent/assent signed by study patient or legally acceptable representative * Patients need to have been compliant with the skin protection measures through the entire duration of the screening period Key Exclusion Criteria: * Treatment with dupilumab in the past * Patients with a positive patch test reaction that are deemed to be clinically relevant as the current cause of the hand and foot dermatitis * Patients with documented exposure to irritants believed to be a predominant cause of the current hand and foot dermatitis * Treatment with systemic corticosteroids or non-steroidal immunosuppressive drugs within 4 weeks prior to baseline * Known history of HIV/HBV/HCV infection * Pregnant or breastfeeding women or planning to become pregnant or breastfeed during the patient's participation in this study * Women of childbearing potential (WOCBP) who are unwilling to practice highly effective contraception prior to the initial dose/start of the first treatment and during the study NOTE: Other protocol d…